Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
暂无分享,去创建一个
D. Dingli | A. Dispenzieri | R. Kyle | M. Gertz | J. Lust | M. Lacy | S. Hayman | F. Buadi | P. Kapoor | R. Go | S. Rajkumar | L. Hwa | S. Kumar | S. Russell | N. Majithia
[1] S. Vincent Rajkumar,et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies , 2015, American journal of hematology/oncology.
[2] S. Trudel,et al. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents , 2015, Bone Marrow Transplantation.
[3] M. Boccadoro,et al. Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.
[4] D. Dingli,et al. Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myeloma , 2012, Cancer.
[5] Hermann Brenner,et al. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. , 2011, The oncologist.
[6] M. Dimopoulos,et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.
[7] P. Moreau,et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Horsman,et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. , 2009, Blood.
[9] B. Barlogie,et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. , 2008, Blood.
[10] D. Dingli,et al. Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.
[11] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[12] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[13] M. Baccarani,et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Trudel,et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Therneau,et al. Clinical course of patients with relapsed multiple myeloma. , 2004, Mayo Clinic proceedings.
[16] J. Crowley,et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[18] P. Ravaud,et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.
[19] R A Kyle,et al. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2014, Leukemia.
[20] M. Gordon. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .
[21] P. Sonneveld,et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials , 2007, Leukemia.
[22] C. Porta,et al. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. , 2003, European journal of cancer.
[23] B. Barlogie,et al. The growth fraction of human myeloma cells. , 1981, Blood.